Dhillon outlined that over the next 90 days and into 2026, the company will "generate a more complete picture of nimasimab's potential using insights from our PK and PD modeling and the ongoing ...

Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 /Champions Oncology, Inc.

Modella AI has signed a multi-year agreement with AstraZeneca to expedite AI-driven oncology clinical development. The partnership will give AstraZeneca access to Modella AI’s multi-modal foundation ...

Using patent intelligence data from the FounderNest platform, alongside funding, partnership, and deployment signals across ...